Hallak M, Irtenkauf S M, Janusz C A, Cotton D B
Department of Obstetrics and Gynecology, Wayne State University/Hutzel Hospital, Detroit, MI 48201.
Am J Obstet Gynecol. 1993 Sep;169(3):695-700. doi: 10.1016/0002-9378(93)90645-y.
The objective of this study was to develop an experimental rat hippocampal seizure model based on the stimulatory effects of N-methyl-D-aspartate and to determine the inhibitory effects of MK-801 on N-methyl-D-aspartate-induced seizures.
Two separate experiments were performed. In the first experiment chemitrode-implanted rats were injected intracranially with increasing doses (5, 10, 20, and 30 micrograms) of N-methyl-D-aspartate into the hippocampus. Various electrophysiologic and behavioral parameters were examined to determine the dose required to reliably elicit hippocampal seizure activity without having toxic effects on the rats. In the second experiment rats were given an intraperitoneal injection of MK-801 (0.5 or 1 mg/kg), followed 20 minutes later by an intracranial injection of N-methyl-D-aspartate (20 or 30 micrograms). The ability of MK-801 to suppress N-methyl-D-aspartate-induced seizure activity was assessed in this experiment.
Intrahippocampal injection of 20 micrograms of N-methyl-D-aspartate produced the shortest electrical seizure latency (193 +/- 72 seconds, p < 0.01). At this dose seizure was achieved in 80% (four of five of the animals, and the highest numbers of electrical seizures per animal were produced (2.2 +/- 0.8, p < 0.05). The group that received 30 micrograms of N-methyl-D-aspartate had a shorter latency, a longer duration of behavioral seizure and a higher number of behavioral seizures (p < 0.05). However, this group suffered a 60% (three of five) mortality rate. The addition of MK-801 significantly decreased the number of seizures per animal and the total seizure duration (p < 0.05). MK-801 also reduced the latency period.
Intracranial injection of 20 micrograms of N-methyl-D-aspartate produced reliable hippocampal seizure activity without mortality. MK-801 at a dose of 1 mg/kg injected intraperitoneally had significant inhibitory effects on this seizure model.
本研究的目的是基于N-甲基-D-天冬氨酸的刺激作用建立实验性大鼠海马癫痫模型,并确定MK-801对N-甲基-D-天冬氨酸诱导的癫痫发作的抑制作用。
进行了两个独立的实验。在第一个实验中,将化学电极植入大鼠颅内,向海马内注射递增剂量(5、10、20和30微克)的N-甲基-D-天冬氨酸。检查各种电生理和行为参数,以确定在不对大鼠产生毒性作用的情况下可靠诱发海马癫痫活动所需的剂量。在第二个实验中,给大鼠腹腔注射MK-801(0.5或1毫克/千克),20分钟后进行颅内注射N-甲基-D-天冬氨酸(20或30微克)。在该实验中评估MK-801抑制N-甲基-D-天冬氨酸诱导的癫痫发作活动的能力。
海马内注射20微克N-甲基-D-天冬氨酸产生最短的电癫痫潜伏期(193±72秒,p<0.01)。在此剂量下,80%(五只动物中的四只)实现了癫痫发作,并且每只动物产生的电癫痫发作次数最多(2.2±0.8,p<0.05)。接受30微克N-甲基-D-天冬氨酸的组潜伏期较短,行为性癫痫发作持续时间较长,行为性癫痫发作次数较多(p<0.05)。然而,该组的死亡率为60%(五只中的三只)。添加MK-801显著减少了每只动物的癫痫发作次数和癫痫发作总持续时间(p<0.05)。MK-801还缩短了潜伏期。
颅内注射20微克N-甲基-D-天冬氨酸可产生可靠的海马癫痫活动且无死亡。腹腔注射1毫克/千克剂量的MK-801对该癫痫模型有显著抑制作用。